How long-term Sandostatin (octreotide) use can lead to gallstones
Sandostatin (octreotide) can reduce gallbladder contractility, which can slow bile flow. Over time, that can promote bile sludge and then gallstones. This is why gallbladder monitoring is commonly recommended during treatment, especially with longer exposure. [1]
Who is most at risk?
Risk tends to be higher when gallbladder function is more suppressed and when treatment continues for months rather than weeks. Patients who already have gallbladder disease, or who are prone to bile sludge or stone formation, are generally more likely to develop problems during therapy. [1]
What symptoms should patients watch for?
Gallstones can be silent, but they may also cause symptoms such as right upper abdominal pain, pain after fatty meals, nausea, vomiting, or fever if inflammation or infection develops. Any new or worsening abdominal pain during Sandostatin therapy should be evaluated promptly. [1]
What do clinicians typically do if gallstones are found?
If gallstones are detected, the key question is whether they are causing symptoms. Many cases are managed with observation, symptom control, and repeat assessment of the gallbladder. If there are complications (for example, acute inflammation or infection), clinicians may consider treatment options such as procedures or surgery depending on severity and clinical status. [1]
Can stopping Sandostatin make gallstones go away?
Gallstone formation related to impaired gallbladder emptying can improve after therapy is stopped, but existing stones may persist. Decisions about continuing or stopping treatment depend on the underlying reason for Sandostatin and the patient’s gallbladder findings. [1]
What monitoring is recommended during treatment?
Because the risk increases with prolonged use, clinicians commonly monitor for gallbladder issues during long-term octreotide treatment, often including ultrasound assessments when indicated. [1]
Sources:
[1] FDA prescribing information for Sandostatin (octreotide) — gallbladder effects/gallstones and monitoring (Drug label): https://www.accessdata.fda.gov/scripts/cder/daf/